drug · small molecule
UGN-103
Phase 3updated 3mo agoby $URGN UroGen Pharma Ltd.🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 7- drugUGN-1041 co-mentions · 1 sources
- drugJelmyto1 co-mentions · 1 sources
- companyAll India Institute of Medical Sciences1 co-mentions · 1 sources
- companyAll India Institute of Medical Sciences Bathinda1 co-mentions · 1 sources
- tagOphthalmology1 co-mentions · 1 sources
- drugmitomycin1 co-mentions · 1 sources
- drugmitomycin SR1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 32 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying UGN-103
- phase3A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- phase3Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
- phase3A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
- phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- phase3A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
- N/AAdaptive Radiation in Anal Cancer
- phase3A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
- phase4Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
News(1)
- Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 YearsTwo doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.onclive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that